Dexcom Beats EPS, Guidance Miss, Shares Fall

Dexcom reported Q1 adjusted EPS of $0.56, topping the $0.47 consensus by $0.09.
Revenue rose 15% YoY to $1.19 bn, beating the $1.17 bn estimate, while U.S. sales grew 11% and international sales jumped 26% (reported).
Full‑year fiscal 2026 revenue guidance of $5.16‑$5.25 bn (midpoint $5.205 bn) fell short of the $5.226 bn analyst consensus, prompting a 5.9% share decline.
Dexcom raised FY2026 operating margin to 23‑23.5% and EBITDA margin to 31‑31.5%, kept gross profit margin 63‑64%, cash $2.42 bn.